Personalized, Targeted Human Antibody (hAb) Therapeutics against severe pneumonia. Therapeutic was created using OMRF’s patent-pending methodology to rapidly isolate and clone human antibodies produced by a “memory” response to vaccination or infection. This is a preclinical spinout company from Accele Biopharma. They are currently (4/3/2013) owned at 100% by Accele Biopharma. They have finalized the license agreement with OMRF as of 4/1/2013.